Evidence map›Paper›PMID 30475212›Full record

SynthesisThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2019

Lamivudine's efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis.

Pooyan Khalighinejad, Seyed Moayed Alavian, Mohammad Gholami Fesharaki, Rozita Jalilianhasanpour

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Broad spectrum antiviral nucleosides-Our best hope for the future.Annual reports in medicinal chemistry · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Pooyan KhalighinejadIsfahan University of Medical Sciences School of Medicine, Isfahan, Iran.
Seyed Moayed AlavianMiddle East Liver Disease Center, Iran Hepatitis Network, Tehran, Iran;Research Centre for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad Gholami FesharakiDepartment of Biostatistics, Tarbiat Modares University School of Medical Sciences, Tehran, Iran.
Rozita JalilianhasanpourTehran University of Medical Sciences School of Medicine, Tehran, Iran.
Baqiyatallah University of Medical Sciences · IRIsfahan University of Medical Sciences · IRTarbiat Modares University · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsMother-to-child transmission (MTCT) is a common transmission mode of hepatitis B virus (HBV). It has been shown that the infection may occur in some infants despite the use of immunoprophylaxis, and many studies have demonstrated the efficacy of antivirals such as lamivudine to reduce such events. MATERIALS AND

methodsA meta-analysis was conducted concerning the efficacy and safety of lamivudine during pregnancy, in the prevention of vertical transmission of HBV infection. Studies were identified by searching various databases up to January 2016 for variations of the following phrase: "lamivudine AND (pregnancy or pregnant) AND (HBV or hepatitis)." Subjects who had received lamivudine were included in the case group, and those who had not were included in the control group.

resultsOur search identified a total number of 881 citations, of which 25 studies (with a total number of 2,667 pregnant women) were included in the meta-analysis. The analysis showed a significant difference between the seropositive HBsAg infants from the case and control groups (RR= 16.97, 95% confidence interval 8.36-34.45), which is the most critical factor in determining the MTCT of HBV. No significant difference was reported between the prevalence of side effects in the case and control groups.

conclusionThis meta-analysis strongly suggests the use of lamivudine in the prevention of HBV vertical transmission in carrier pregnant women with the HBV DNA levels greater than 106 copies/mL. And for women with the HBV viral loads lower than 106 copies/mL, we suggest clinicians to examine the use of lamivudine on a case-to-case basis, noting that lamivudine seems to be a safe drug for the mother and the fetus.

Indexed as

AdultAntiviral AgentsFemaleHepatitis B, ChronicHumansInfant, NewbornInfectious Disease Transmission, VerticalLamivudineMalePregnancyPregnancy Complications, InfectiousPrenatal CareTreatment OutcomeAntiviral AgentsLamivudine

Identifiers

PMID30475212
PMCPMC6389296
OpenAlexW2898590219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.